Business
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update. To access the live conferen
About this update from Atea Pharmaceuticals, Inc.
[{"type":"image","alt":"Atea Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Atea Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ykAWgy3tgXn4RMmG471nog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOA--/https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30","width":300,"height":170}},"lazy":false},{"type":"text","content":"BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update.","length":472,"tagName":"p"},{"type":"text","content":"To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please dial 1-877-407-0779 (U.S.) or 1-201-389-0914 (International) and use conference ID number 13759581. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.","length":573,"tagName":"p"},{"type":"text","content":"About Atea Pharmaceuticals","length":26,"tagName":"p"},{"type":"text","content":"Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipe...